Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Accured Expenses: 2011-2025

Historic Change in Accured Expenses for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $1.3 million.

  • Niagen Bioscience's Change in Accured Expenses rose 35.84% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 398.75%. This contributed to the annual value of $1.2 million for FY2024, which is 44.06% down from last year.
  • As of Q3 2025, Niagen Bioscience's Change in Accured Expenses stood at $1.3 million, which was up 179.03% from -$1.7 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Change in Accured Expenses high stood at $1.6 million for Q1 2022, and its period low was -$1.8 million during Q2 2024.
  • Over the past 3 years, Niagen Bioscience's median Change in Accured Expenses value was $972,000 (recorded in 2024), while the average stood at $385,909.
  • As far as peak fluctuations go, Niagen Bioscience's Change in Accured Expenses tumbled by 58,566.67% in 2021, and later skyrocketed by 1,756.67% in 2023.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Change in Accured Expenses stood at $150,000 in 2021, then spiked by 287.33% to $581,000 in 2022, then slumped by 48.36% to $300,000 in 2023, then soared by 269.00% to $1.1 million in 2024, then skyrocketed by 35.84% to $1.3 million in 2025.
  • Its Change in Accured Expenses stands at $1.3 million for Q3 2025, versus -$1.7 million for Q2 2025 and $1.2 million for Q1 2025.